| __timestamp | Amicus Therapeutics, Inc. | Dynavax Technologies Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 17763000 |
| Thursday, January 1, 2015 | 47269000 | 22180000 |
| Friday, January 1, 2016 | 71151000 | 37257000 |
| Sunday, January 1, 2017 | 88671000 | 27367000 |
| Monday, January 1, 2018 | 127200000 | 64770000 |
| Tuesday, January 1, 2019 | 169861000 | 74986000 |
| Wednesday, January 1, 2020 | 156407000 | 79256000 |
| Friday, January 1, 2021 | 192710000 | 100156000 |
| Saturday, January 1, 2022 | 213041000 | 131408000 |
| Sunday, January 1, 2023 | 275270000 | 152946000 |
In the competitive world of biotechnology, managing operational expenses is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Amicus Therapeutics, Inc. and Dynavax Technologies Corporation from 2014 to 2023. Over this period, Amicus Therapeutics has seen a significant increase in SG&A expenses, growing by approximately 1,230%, from $20.7 million in 2014 to $275.3 million in 2023. In contrast, Dynavax Technologies Corporation's SG&A expenses rose by about 760%, from $17.8 million to $152.9 million. This disparity highlights Amicus's aggressive expansion strategy, potentially reflecting its investment in market penetration and operational scaling. Meanwhile, Dynavax's more conservative growth in expenses suggests a focus on optimizing existing operations. Understanding these trends provides valuable insights into each company's strategic priorities and financial health, offering a window into their future trajectories.
Intra-Cellular Therapies, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Bio-Techne Corporation or Amicus Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Blueprint Medicines Corporation and Dynavax Technologies Corporation
Madrigal Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Grifols, S.A. vs Dynavax Technologies Corporation Trends and Insights
CymaBay Therapeutics, Inc. vs Amicus Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing PTC Therapeutics, Inc. and Amicus Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of MorphoSys AG and Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. and Soleno Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Breaking Down SG&A Expenses: Amicus Therapeutics, Inc. vs MannKind Corporation
Selling, General, and Administrative Costs: Vericel Corporation vs Dynavax Technologies Corporation